{
    "2020-12-09": [
        [
            {
                "time": "2020-12-09",
                "original_text": "新冠疫苗是航空股“救命药”？业内：板块回暖仍待需求恢复",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "航空股",
                        "救命药",
                        "板块回暖",
                        "需求恢复"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "航空"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "金域医学：君睿祺、君联茂林合计减持1.4514%公司股份 减持股份",
                "features": {
                    "keywords": [
                        "金域医学",
                        "君睿祺",
                        "君联茂林",
                        "减持"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "金域医学(603882.SH)：君睿祺及君联茂林减持期届满合计减持666.92万股 减持股份",
                "features": {
                    "keywords": [
                        "金域医学",
                        "君睿祺",
                        "君联茂林",
                        "减持期届满",
                        "减持"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "医药生物2021年投资策略报告：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "报告"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
                "features": {
                    "keywords": [
                        "医药",
                        "白酒",
                        "2021年度策略",
                        "次新股",
                        "圣农发展"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "白酒"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "国内财经媒体头版2020年12月9日星期三",
                "features": {
                    "keywords": [],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药生物",
                        "投资策略",
                        "展望"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}